Product
BCMA CART
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
Phase 1 Study of CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2036-03-01